abiraterone,olaparib
astrazeneca,janssen,merck
['abira', 'abiraterone', '1357o', 'biomarker', 'propel', 'olaparib', 'prostate', 'crpc', 'marker ']
#esmo22 abs# 1357o: updated results from the phase 3 propel trial in mcrpc #prostatecancer showed rpfs benefit of using abiraterone + olaparib vs abiraterone biomarker subgroup analysis. significant pfs benefit, os trending favorably 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl195o3E